- Novartis hit by China, emerging market slowdown: CEO on CNBC (reuters.com)Novartis will weather the EM market storm: CEO (cnbc.com)
Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits,…Despite the increasing risks,..the Swiss company was not pulling back from emerging markets, rather relying on the strength of generics in China to drive business growth…We are going to live through the volatility…
- McKesson’s corporate wellness program saves money, gains accolades (drugstorenews.com)
McKesson… announced it has been selected as a 2015 C. Everett Koop National Health Award recipient in recognition for the company’s employee health and wellness program…Our...program…promotes the physical, mental and social wellbeing of our employees and their families…focus is on improving health, we’re pleased that the wellness initiatives have created opportunities to lower health care costs…includes health risk assessments and screenings, educational tools, physical activities and prevention efforts. The program has had increased employee engagement each year since its inception…and has evolved from a payout for completed health assessments into a comprehensive health promotion program with an integrated incentive structure that rewards participants for healthy behaviors.
- Target pharmacy workers form union, first in company’s history (reuters.com)CVS announces Union Cooperation Agreement in 500 stores (cvsworker.com)NLRA Process (Typical Election Timeline) (cvsworker.com)
pharmacy workers within Target Corp's store in Brooklyn, New York, have won a vote to form a microunion, making it the first unionized store at the retailer since its inception in 1902…a group of pharmacists and pharmacy technicians won an initial ballot, 7-2, to form the union,.. "It is a big win for us," said…director of the United Food and Commercial Workers union that supported the vote…
- Reputation matters: Why the rift between pharma and patients is ballooning (biopharmadive.com)
What’s in a reputation?.. A lot… The level of antagonism toward pharma in the U.S. is a surprise... considering how deep it goes.. Overall, the corporate reputation of the entire biopharma industry was low, verging on abysmal…"[T]he pricing of oncology drugs is driving a rift between pharma and patients."… At the other end of the healthcare reputation spectrum.. retail pharmacies at the very top…75% of those surveyed believed that retail pharmacists have an "excellent" or "good" corporate reputation. Patients responded positively to the community-based, patient-oriented focus of retail pharmacists,..
- Pharmacy Technician License Requirements by State (pharmacytimes.com)
As pharmacy technicians take on increasingly important roles and responsibilities, the regulations governing the profession continue to strengthen…Organizations such as the Pharmacy Technicians Certification Board are able to provide a national standard for technicians, but in the end, each state determines its own minimum requirements for working as a pharmacy tech… Current and aspiring techs unsure of their state’s laws can consult the following reference guide that explains how to become licensed as a pharmacy technician in each state.
- Health systems acquiring non-acute care clinics for growth (drugstorenews.com)Who needs beds? New ambulatory centers offer everything except inpatient care (modernhealthcare.com)
Large U.S. health systems are buying clinics, physician practices and digital resources in search of growth opportunities in lieu of traditional acquisition of other hospitals,… which is being driven by the need to gain economies of scale, shift from volume to value-based care, compete in local markets and expand digital health and healthcare IT capabilities…To deal effectively with greater complexity, higher volumes and other changes resulting from increased acquisitions, industry providers will need to manage their businesses with the mindset of a portfolio manager…
- Department of Health and Human Services, AstraZeneca to develop antibiotics (reuters.com)
Department of Health and Human Services said …signed a deal with British drugmaker AstraZeneca Plc to develop antibiotics... will share costs…to develop a portfolio of drugs to treat illnesses caused by bioterrorism agents and antibiotic-resistant infections… Biomedical Advanced Research and Development Authority .. will initially provide $50 million,… The first drug candidate to be explored is a combination of two antibiotics, Aztreonam and Avibactam
- Carson Tahoe Health partners to unveil Sierra Pediatric Blood and Cancer Consortium (nevadaappeal.com)
Three Northern Nevada hospitals along with area provider groups are ganging up on childhood cancer…Renown health, Saint Mary’s, Carson Tahoe Health, Washoe County and the Access to Healthcare Network joining forces to establish the first full-time clinic in Northern Nevada to provide complete services to child cancer patients… the Sierra Pediatric Blood and Cancer Consortium...
- Update: Pager, Zipdrug partnership puts docs, meds on demand (drugstorenews.com)
Health care just got a whole lot more convenient in Manhattan, where a pair of health app developers …began coupling their offerings in what may become the ultimate in fast service — doctors to your door by way of Pager quickly followed by an on-demand prescription delivery from Zipdrug...Pager was launched…a healthcare startup reinventing the traditional doctor-patient experience…connects patients to board-certified doctors who make home, office or hotel visits within two hours…. Zipdrug…employs a trained delivery staff who picks up prescriptions at the pharmacy of the patient's choice and delivers them to the patient's doorstep.
- Intra-Cellular Surges on Optimistic Outlook for Schizophrenia Drug (thestreet.com)
Schizophrenia patients treated with an experimental drug from Intra-Cellular Therapies reported fewer antipsychotic symptoms compared to a placebo in a large, phase III study, the company said Wednesday. Intra-Cellular shares climbed 73% to $45.36, an all-time high, on the positive results from the study and the belief that the drug, ITI-007, could generate billions of dollars in schizophrenia sales if eventually approved.









